Skip to main content
Journal of Translational Medicine logoLink to Journal of Translational Medicine
. 2026 Aug 25;24:1332. doi: 10.1186/s12967-026-08767-x

Shikonin triggers apoptosis in lung adenocarcinoma through the FHL2-FOXO1 signaling axis

Shiqun Chen 2,#, Meirong Zhou 3,#, Wen Zhang 3,#, Jiyong Zhong 1,#, Wenqian Han 1,2, Zhaoxuan Wang 1, Shiqing Wang 1, Chundong Gu 1,4, Zhenlong Yu 5,✉, Shilei Zhao 1,4,✉
PMCID: PMC13693113  PMID: 42919378

Abstract

Background

FHL2 is an oncogenic scaffold protein that is overexpressed in lung adenocarcinoma (LUAD), making it a promising therapeutic target. SHK, a natural naphthoquinone, exhibits antitumor activity, but its molecular mechanism in LUAD, particularly its relationship with FHL2, remains unclear.

Aim of this study

The present study aimed to define the effects of SHK on NSCLC and identify the potential underlying molecular mechanisms.

Methods

The anti-tumor effects of SHK were evaluated in LUAD cell lines (A549andH1299) and a patient-derived xenograft (PDX) model using CCK-8, colony formation, Transwell, and flow cytometry assays. Integrated proteomics, bioinformatics, molecular docking, and cellular thermal shift assays (CETSAs) were employed to identify the direct target of SHK. The underlying mechanism was investigated through co-immunoprecipitation (Co-IP), Western blotting, qRT-PCR, cycloheximide (CHX) chase assays, and immunofluorescence/immunohistochemiscal (IF/IHC) staining.

Results

In both in vitro and PDX models, SHK potently inhibited LUAD growthand metastasisand induced cell death. At the molecular level, FHL2 was identified as a direct target of SHK. The direct binding of SHK to FHL2 promoted its proteasomal degradation, thereby disrupting the FHL2-FOXO1 complex. The dissociation of this complex increased FOXO1 acetylation and promoted its nuclear translocation, leading to the subsequent activation of the caspase cascade and apoptosis.

Conclusion

Our findings indicate a novel signaling pathway through which SHK inhibits LUAD: by directly targeting FHL2 for degradation, SHK disrupts the FHL2-FOXO1 complex, which activates FOXO1-mediated transcription and triggers apoptosis. This study not only provides mechanistic insight into the antitumor function of SHK but also identifies the FHL2-FOXO1 axis as a potential therapeutic target for LUAD.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12967-026-08767-x.

Keywords: SHK, FHL2, FOXO1, Lung adenocarcinoma, Apoptosis

Introduction

Lung cancer is the leading cause of cancer-related morbidity and mortality worldwide. Although recent advances in low-dose computed tomography (LDCT) screening, immune checkpoint inhibitors (ICIs), and targeted therapies have modestly improved five-year survival rates, patients with advanced lung cancer continue to face inevitable challenges of drug resistance and disease recurrence [1]. Histologically, lung cancer is broadly categorized into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with the latter comprising adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and other subtypes [2]. As the most prevalent histological form of NSCLC, lung adenocarcinoma (LUAD) presents considerable clinical challenges because of its marked tumor heterogeneity and unfavorable prognosis [3]. Recent advances in understanding LUAD pathogenesis have been made. The widespread clinical use of small-molecule targeted therapies and PD-1/PD-L1 inhibitors has also progressed, these developments have led to gradually improved patient outcomes [4, 5]. Nonetheless, therapeutic success remains constrained by the emergence of drug resistance and apoptotic evasion, often leading to suboptimal clinical responses. Metastasis, relapse, treatment resistance, and drug-related toxicity continue to pose major hurdles in the management of advanced LUAD [6]. Hence, the development of novel diagnostic approaches and innovative small-molecule therapeutics is urgently needed. A deeper mechanistic understanding of LUAD progression and the discovery of molecular-level therapeutic targets are critically needed.

FHL2 is a key member of the “LIM-only” protein family (LIM stands for Lin-11, Isl-1, and Mec-3), and is characterized by four full LIM domains and one N-terminal half-LIM domain [7]. FHL2 performs exhibits context-dependent and cell type-specific functions [8], participates in processes such as muscle, bone, and cardiac development, and serves as a biomarker for idiopathic pulmonary fibrosis (IPF) [9–12]. Notably, FHL2 plays a dual role in tumorigenesis, acting as either an oncoprotein or a tumor suppressor depending on the cancer type; its expression is downregulated in breast cancer and liver cancer, where it suppresses tumor growth, whereas it is upregulated in lung cancer, gastric cancer, colorectal cancer, pancreatic cancer, prostate cancer, cervical cancer, and ovarian cancer, promoting tumor cell proliferation, invasion, and metastasis [13]. FHL2 lacks intrinsic DNA-binding activity, shuttles between the cytoplasm and nucleus, and regulates multiple cellular signaling pathways through interactions with various transcription factors [14]. In non-small cell lung cancer (NSCLC), studies have confirmed that FHL2 activates the Wnt/β-catenin signaling pathway, promotes the epithelial‒mesenchymal transition (EMT) to regulate proliferation and apoptosis, and increases vascular permeability via the VEGFA/Akt/mTOR pathway [15, 16]. Furthermore, FHL2 overexpression in cancer-associated fibroblasts (CAFs) promotes cancer cell migration and invasion, as well as in vitro angiogenic potential and in vivo metastatic dissemination [17]. FHL2 plays important roles in lung cancer. It is now recognized as a potential biomarker for diagnosis and prognosis, as well as a promising therapeutic target.

Shikonin (SHK), a bioactive naphthoquinone derived from Lithospermum erythrorhizon [18], exhibits potent antitumor activity in various cancers, including breast, gastric, and colon cancer [19–21]. Studies have shown that SHK inhibits tumor growth, progression, and metastasis through multiple pathways, such as modulating cancer cell proliferation, apoptosis, autophagy, and necroptosis, and inducing immunogenic cell death (ICD) [22, 23]. Furthermore, SHK modulates the immunosuppressive tumor microenvironment by inhibiting tumor cell glycolysis and repolarizing tumor-associated macrophages (TAMs) [24, 25]. However, the precise molecular mechanisms underlying the role of SHK in the treatment of (LUAD) remain incompletely defined, in particular the induction of apoptosis via the FHL2-FOXO1 signaling axis has rarely been reported.

We combined cellular assays with PDX models to elucidate the mechanism of SHK-mediated LUAD suppression. SHK dose-dependently inhibited proliferation and migration. It also promoted apoptosis in LUAD cells. Crucially, we identified FHL2 as the direct target of SHK through molecular docking and validated the results using a cellular thermal shift assay (CETSA). The core mechanism involves the SHK-induced disruption of the FHL2–FOXO1 interaction, resulting in increased FOXO1 acetylation and nuclear accumulation. Our study is the first to conclusively demonstrate that SHK specifically induces LUAD cell apoptosis by targeting the FHL2–FOXO1 axis, providing a strong rationale for targeting FHL2 as a novel therapeutic strategy.

Materials and methods

Cell culture

The human NSCLC cell lines A549, NCI-H1299, NCI-H827, and NCI-H322 and BEAS-2Band HEK293T cells were obtained from the American Type Culture Collection (ATCC). Fewer than 30 generations of cells were cultured and passaged. The cell lines were cultured using ATCC -recommended media. HEK293T and BEAS-2B cells were cultured in DMEM supplemented with 10% FBS (Gibco), and A549 cells were cultured in F-12 K medium (HyClone) supplemented with 10% FBS (Gibco).NCI-H1299, NCI-H827, and NCI-H322 cells were cultured in RPMI 1640 medium supplemented with 10% FBS (Gibco). The Cells were maintained in a humidified atmosphere with 5% CO2 at 37 °C.

Cell Counting Kit-8 (CCK8) assay

Cells in the logarithmic growth phase were actively proliferated and seeded into a 96-well plate at a density of 5,000 cells per well to ensure a consistent cell density for subsequent experiments. After attachment, the cells were stimulated with varying concentrations of SHK (0, 0.5, 1.0, 2.0, 4.0, 8.0 µM) for 24–48 h Shikonin (SHK; JOT-11729, >98%) was purchased from Chengdu Pufei De Biotech Co, Ltd (China), and dissolved in DMSO to produce a 5 mM stock solution. A solution containing 10% Cell Counting Kit-8 (CCK-8) was added to each well, and incubated with the cells for 2 h to assess cell viability. The optical density was then measured at 450 nm using a microplate reader (PerkinElmer, Waltham, MA, USA).

Colony formation assay

The inhibitor effect of SHK on he proliferation of LUADcells was assessed using a standardized colony formation assay. A549 and H1299 cells in the logarithmic growth phase were trypsinized and seeded into 6-well plates at a density of 500 cells per well. After cell attachment at 37 °C in a % CO₂ incubator, the cells were treated with various concentrations of SHK (0, 0.5, 1.0, 2.0, and 4.0 µM) and cultured continuously for 14 days until colonies became visible to the naked eye. Colonies were fixed with 4% paraformaldehyde (PFA, Sigma-Aldrich) for 30 min, and stained with 0.1% crystal violet (Beyotime Biotechnology) for 1 h at room temperature before beingphotographed with an ordinary camera.

Transwell assay

Transwell migration assays were conducted using Corning chambers. A549 and H1299 cells were subjected to serum starvation for 6 h and subsequently seeded at a density of 1 × 10⁵ cells/200 µL into the upper chambers, which contained medium supplemented with gradient concentrations of SHK. The lower chambers were loaded with 600 µL of medium supplemented with 10% FBS to serve as a chemoattractant. After 48 h of incubation at 37 °C in a 5% CO₂ atmosphere, The cells that had migrated through the membrane were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. Microscopy images were obtained at 100× magnification, and cell migration was quantified by counting the number of migrated cells using ImageJ software.

Western blot analysis

Treated cells or tissues were lysed using RIPA lysis buffer (Beyotime Biotechnology Co., Ltd., Shanghai, China) supplemented with the protease inhibitor PMSF and a phosphatase inhibitor cocktail, followed by centrifugation to collect the supernatant for protein quantification using a Bicinchoninic Acid (BCA) Protein Assay Kit (Beyotime Biotechnology Co., Ltd.). The proteins were separated by sodium dodecyl sulfate‒polyacrylamide gel electrophoresis (SDS-PAGE) and subsequently transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA). The membranes were blocked with 5% skim milk for a1 -hour, then incubated with primary antibodies at 4 °C overnight, followed by 1-hour incubation with secondary antibodies at room temperature. After the membranes were washed with TBST, protein signals were detected using Western Bright ECL substrate (Tanon Science and Technology Co., Ltd., Shanghai, China), and protein levels were determined using ImageJ software. The antibodiesused in this study were as follows:

MMP9 (Proteintech ,60600-1-Ig, 1:1000), PCNA (Proteintech,10205-2-AP, 1:2000), anti-pro-PARP (Proteintech, 60555-1-Ig, 1:2000), anti-pro-caspase-3 (Proteintech, 25128-1-AP,1:1000),Bcl-2 (Proteintech,60178-1-Ig, 1:1000), BAX (Proteintech, 50599-2-Ig, 1:1000), FOXO1 (HUABIO, ET1608-25, 1:2000) ,FHL2 ( abcam, ab202584, 1:1000),Secondary antibody was used: Anti-mouse or Anti-rabbit IgG, 1:5000 dilution.

Quantitative RT‑PCR

Total RNA was extracted from human cancerous and normal lung tissues/PDX tissues/A549 and H1299 cells using TRIzol reagent (Hunan Aikerui Bioengineering Co., Ltd., China) according to the manufacturer’s instructions. Subsequently, 1 µg of RNA was used to synthesize complementary DNA (cDNA) with a RevertAid First Strand cDNA Synthesis Kit (MonAmp, China). A quantitative real-time PCR (qRT‒PCR) analysis was performed on a CFX96 Real-Time PCR Detection System (Bio-Rad, USA) using Power SYBR Green Master Mix (MonAmp, China) to assess mRNA expression levels. β-Actin was used as a housekeeping gene, and relative gene expression was calculated using the 2^(−ΔΔCT) method.The primers used were as follows: FHL2-F, CTGGAGACTAGGCTGGCATT; FHL2-R, CCGTGGTGATGGGCTTTTTG; FOXO1-F, AGGGTTAGTGAGCAGGTTACAC; FOXO1-R, CTGCCCCAAATACCTGTGGT. β-actin-F, CCCGGAGAAGAGCTACGAG; and β-actin-R-CGTACAGGTCTTTGCGGATG.

Flow cytometry assay

The percentages of apoptotic cell proportions were assessed using flow cytometry with instruments supplied by BD Biosciences (Shanghai, China). A549 and H1299 cells treated with various concentrations of SHK were harvested using EDTA-free trypsin, stained with Annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI), and quantitatively analyzed using flow cytometry to evaluate apoptosis rates. An Annexin V-FITC/PI Apoptosis Detection Kit (KGA 108) was purchased from KeyGEN BioTECH Co., Ltd. (Nanjing, Jiangsu Province, China).It was detected and analyzed using flow cytometry (BD)software.

siRNA interference assay

A549 and H1299 cells were seeded in 6-well plates and transfected at 50–60% confluence. Prior to transfection,3 µL of Lipofectamine™ 2000 transfection reagent (Invitrogen, Carlsbad, CA, USA) was diluted in Opti-MEM and mixed with 5 µL of siRNA (20 µM stock, corresponding to approximately 1.32 µg) according to the manufacturer’s instructions. The mixture was incubated at room temperature for 20 min to allow complexes to form and then added dropwise to the cells. After 6 h, the transfection medium was replaced with complete growth medium supplemented with 10% fetal bovine serum (FBS). Cells were harvested at 48 h post-transfection for mRNA expression analysis by quantitative reverse transcription‒PCR (RT-qPCR) and protein expression usingWestern blotting.The siRNA sequences used in this study were as follows:

sense, 5′-GCAGCCAAUUGGAACCAAGTT-3′and.

; antisense, 5′-CUUGGUUCCAAUUGGCUGCTT-3′.

Transient transfection and establishment of stable cell lines

293T cells were seeded in 10-cm dishes and cultured for 24 h. Prior to transfection, the medium was replaced with serum-free DMEM. The cells were transfected with recombinant plasmids encoding Flag-FHL2 or FOXO1-HA using polyethyleneimine (PEI,;Polysciences, Warrington, PA) at a DNA: PEI ratio of 1:3. After 8 h of incubation, the medium was replaced with complete medium containing 10% FBS. The cells were cultured for an additional 48 h and harvested to determine target protein expression by Western blotting. Lentiviral packaging was performed by cotransfecting 293T cells with the recombinant plasmid along with the packaging plasmids psPAX2 (Addgene, Cambridge, MA) and pMD2.G (Addgene) using polyethyleneimine (PEI). Following 48 h of transfection, viral supernatants were harvested, filtered through 0.45-µm membranes, and used to infect A549 and H1299 cells with 50% (v/v) viral supernatant-containing medium supplemented with 8 µg/mL polybrene for 24 h to establish stable cell lines; stable clones were subsequently selected with puromycin-containing medium (preoptimized concentration of 2–5 µg/mL) for 10–14 days with medium replenishment every 48 h.

Cycloheximide chase (CHX )assay

Cells were pretreated with SHK at a final concentration of 1 µM for 24 h. CHX was added to the culture medium at a concentration of 50 µg/mL, and the cells were collected at 0, 3, 6, and 9 h. The samples were subsequently centrifuged at4°C. The supernatants were mixed with loading buffer and analyzed by SDS‒PAGE followed by Western blotting.

Cellular thermal shift assay (CETSA)

A549 cell lysates were collected and equally divided into two aliquots, which were treated with DMSO or SHK, followed by an incubation at room temperature for 2 h. The suspensions were aliquoted, heated in a PCR machine at specified temperatures (39–60 °C) for 4 min, and then cooled at room temperature for 5 min. The samples were subsequently centrifuged at 20,000 × g for 15 min at4°C. The supernatants were mixed with loading buffer and separated by SDS‒PAGEfor a subsequent immunoblotting analysis of FHL2 expression.

Coimmunoprecipitation (Co-IP) assay

For immunoprecipitation, 600 µg of total protein was diluted to 500 µL using binding buffer. Experimental samples were incubated with 2 µg of anti-Flag, anti-HA, or anti-FOXO1 antibodies, while control samples received 2 µg of species-matched IgG. Following 1-h vortexing at 4 °C, 15 µL of pre-washed Protein G magnetic beads was added, and the mixture was incubated overnight with gentle agitation. Magnetic separation was subsequently performed: the supernatants were discarded and the beads were washed three times with 500 µL of ice-cold binding buffer. Bound proteins were eluted in 50 µL of 2× Laemmli buffer by boiling at 95 °C for 10 min. The eluates were collected after the final magnetic separation for Western blot analysis.

Immunofluorescence (IF) and immunohistochemical (IHC) staining

IF staining

A549 and NCI-H1299 cells in the logarithmic growth phase were seeded onto glass coverslips. After adhering, the cells were treated with SHK for 48 h. The cells were then washed with phosphate-buffered saline (PBS) to remove the residual culture medium, fixed with paraformaldehyde, and washed three times with PBS. The cells were subsequently permeabilized with 0.1% Triton X-100 for 30 min and blocked with 5% bovine serum albumin (BSA) at room temperature for 1 h. The cells were then incubated with an anti-FHL2 primary antibody (1:300) and anti-FOXO1 primary antibody (1:100) overnight at 4 °C. After being washed, the cells were incubated with an Alexa Fluor 594-labeled secondary antibody (1:200) for 1 h at room temperature, after which they were subjected to DAPI staining for nuclear counterstaining. Fluorescence images were captured using a fluorescence microscope.

IHC staining

Paraffin-embedded tissue sections.  (4–6 μm) were deparaffinized in xylene and rehydrated through a graded ethanol series. Endogenous peroxidase activity was blocked by an incubation with 3% hydrogen peroxide for 20 min at room temperature. Antigen retrieval was performed in 10 mM citrate buffer (pH 6.0) using microwave irradiation for 20 min. The sections were then incubated overnight at 4 °C with primary antibodies in a humidified chamber. Following washes with PBS, the sections were treated with species-specific biotinylated secondary antibodies for 1 h at room temperature. The signal was visualized using an ABC Elite Kit with DAB chromogen. Counterstaining was performed with Mayer’s hematoxylin for 45 s, followed by dehydration through increasing ethanol concentrations and clearance with xylene. The sections were permanently mounted with resinous mounting medium. Images were acquired using a bright-field microscope (Nikon Eclipse E200, 20× objective).

Molecular docking analysis

The X-ray crystallographic structure of FHL2 (PDB ID: 2MIU) and ID1 (PDB ID: 2P57) were retrieved from the Protein Data Bank (PDB, https://www.rcsb.org). The three-dimensional structure of SHK was obtained from the PubChem database (Compound ID: 479503 MF: C16H16O5 MW: 288.29 g/mol https://pubchem.ncbi.nlm.nih.gov) and converted to Mol2 format using OpenBabel GUI (version 3.1.1). Protein structures were preprocessed with PyMOL (version 2.60) by removing water molecules, metal ions, and bound ligands. Hydrogen atoms and Gasteiger charges were added to both proteins and SHK using AutoDockTools (version 1.5.7). Grid parameters were defined to encompass the putative binding sites, with grid box dimensions set to 60 × 60 × 60 Å and a spacing of 0.375 Å.Molecular docking was performed using the Lamarckian genetic algorithm (LGA) with the default parameters (energy evaluations:50). The resulting docking poses were visualized and analyzed using PyMOL to evaluate binding modes, hydrogen bonding, and hydrophobic interactions.

Cytoplasmic and nuclear protein extraction

Cells were collected by centrifugation at 500 × g for 5 min at 4 °C and washed twice with ice-cold PBS. The kit was purchased from Beyotime Biotechnology (Shanghai, China), with the catalog number P0027.The cell pellet (20–50 × 10⁶ cells) was resuspended in 1 mL of ice-cold cytoplasmic extraction reagent A and incubated on ice for 40 min with intermittent vortexing. After centrifugation at 2,500 × g for 5 min at 4 °C, the supernatant was further centrifuged at 12,000 × g for 10 min at 4 °C. The resulting supernatant was collected as the cytoplasmic protein fraction.The remaining pellet was resuspended in nuclear extraction reagent B and subjected to three repeated centrifugation steps (2,500 × g for 5 min each). The final pellet was then resuspended in 100 µL of nuclear extraction reagent C and incubated on ice for 90 min with frequent vortexing. After centrifugation at 10,000 × g for 10 min at 4 °C, the supernatant was collected as the nuclear protein fraction.Protein samples were mixed with 5× loading buffer, heated in boiling water for 10 min, and rapidly centrifuged. The denatured samples were then subjected to Western blot analysis.

Thermal proteome profiling (TPP) and solvent-induced protein precipitation (SIP) assay

TPP and SIP assays, cell pellets were collected and lysed using PBS containing 1% EDTA-free protease inhibitor cocktail (pH 7.4). The cell suspensions were subjected to three freeze–thaw cycles in liquid nitrogen, and the supernatants were collected after centrifugation and divided into two aliquots. For the TPP assay, the aliquots were treated with 100 µM SHK or DMSO (vehicle control), and heated at 52 °C for 3 min to induce protein denaturation. The soluble proteins remaining in the supernatants were collected for quantitative proteomics analysis. For the SIP assay, the aliquots were treated with an organic solvent mixture (acetone: ethanol: acetic acid = 50:50:0.1) to a final concentration of 1%, and equilibrated at 37 °C with shaking at 800 rpm for 20 min. The supernatants were then collected for quantitative proteomics analysis.

Develop a PDX model to assess the therapeutic effectiveness of SHK

Patient-derived tumor tissues were obtained from The First Affiliated Hospital of Dalian Medical University with written informed consent. All procedures involving human specimens were approved by the Institutional Ethics Committee (Approval No. PJ-KS-KY-2025-431) and were conducted in strict compliance with the Declaration of Helsinki. Fresh LUAD specimens were dissected into fragments of approximately 8 mm³ (ranging from 1.5 × 1.5 × 1.5 mm to 2 × 2 × 2 mm) and subcutaneously implanted into the axillary region of 6-week-old male NYG mice (Vital River Laboratories, Beijing, China) within 2 h after resection under specific pathogen-free (SPF) conditions. All animal experiments were approved by the Animal Ethics Committee of Dalian Medical University (Approval No. XL250619069). Tumor growth was monitored weekly using calipers. When the tumor dimensions reached approximately 1.5 × 1.5 cm, the mice were euthanized by cervical dislocation under isoflurane anesthesia. The harvested tumors were subsequently passaged into secondary BALB/c nude mice (6 weeks old). Mice with successfully engrafted tumors (volume > 200 mm³) were randomly assigned (n= mice 5 per group) to receive either SHK (2.5 or 5 mg/kg) or vehicle control (saline), administered intraperitoneally every other day for 14 consecutive days. The tumor volume was calculated using the following formula: V = (length × width²)/2. Humane endpoints were strictly observed, and the mice were euthanized either when the tumor volume exceeded 1,800 mm³ or upon reaching the predefined experimental endpoint. All excised tumor tissues were processed for immunohistochemicalstaining.

Data analysis

Data are mean ± SEM from ≥ 3 independent replicates. Normality was assessed by Shapiro–Wilk test (n < 50) and homoscedasticity by Levene’s test. Normally distributed data were analyzed by Student’s t-test (two groups) or one-way ANOVA with Tukey’s post-hoc test for pairwise multiple comparisons test for comparisons against the control group. Non-normally distributed data were analyzed by Mann–Whitney U test (two groups) or Kruskal–Wallis test with Dunn’s post-hoc test (multiple groups). GraphPad Prism 9.5.1 was used. Significance: *P < 0.05, **P < 0.01, ***P < 0.001, *** P < 0.001.

Results

SHK inhibits LUAD cell proliferation and migration in cellular and PDX models

The effects of SHK on the viability of LUAD cell lines (A549, H322, H827andH1299) and normal bronchial epithelial cells (BEAS-2B) were evaluated using aCCK-8 assay. SHK significantly reduced the survival of LUAD cells in a dose- and time- dependent manner, with tumor cells exhibiting greater sensitivity than BEAS-2B cells (Fig. 1A). H1299 and A549 cells were selected for further investigation of drug sensitivity, therefore, H322 and H827 cells were excluded from subsequent studies, and A549 and H1299 cells were selected as the primary research models. Similarly, the results of the colony formation assays revealed that compared with the control treatment, SHK treatment reduced both colony number and diameter (Fig. 1B). Transwell migration assays further revealed a concentration-dependent decrease in the number of migrated cells upon SHK treatment (Fig. 1C). Furthermore, Western blot analysis confirmed that SHK downregulated the expression of the proliferation marker PCNA and the metastasis-associated protein MMP-9 in a concentration-dependent manner (Fig. 1D-E).

Fig. 1.

Fig. 1

The impact of Shikonin (SHK) on non-small cell lung cancer (NSCLC) Cellular and patient-derived xenograft (PDX) tumor model Activity. (A) NSCLC cells A549,H322༌H827༌H1299 and Human Bronchial Epithelial Cells(BEAS-2B)were cultured with the indicated concentrations of SHK for 24 and 48 h, after which the cell viability was determined using the CCK-8 assay. (B) Analysis of SHK-Induced Reduction in Colony Formation and Quantification of Colony Numbers. C) SHK-Mediated Inhibition of NSCLC Cell Migration and Quantitative Analysis. D-E) Representative Western Blot Images and Quantitative Analysis of PCNA and MMP-9 Expression Levels. F) Schematic Illustration of SHK Therapeutic Mechanism in PDX Tumor Models. G) Representative Tumor Images in Mouse PDX Models. H) Analysis Tumor Volume Growth Curves in PDX Models. I)Analysis Tumor Weight. J) Body Weight Changes in Tumor-Bearing Mice. K) Statistical Analysis of MMP-9 and PCNA Protein Expression in PDX Models. L) immunohistochemical analysis. These experiments were repeated three times with *P < 0.05, **P < 0.01, ***P < 0.001, ****P <, 0.0001 via one-way analysis of variance (ANOVA)

In addition, a PDX model was established using tumor tissue from patient with a stage IIB (pT2N1M0) LUAD (UICC 9th edition TNM staging) to evaluate the efficacy of SHK in vivo. Following intraperitoneal SHK administration (2.5 or 5 mg/kg every other day for 14 days), the tumor volume and weight were significantly reduced compared to with those of the controls (Fig. 1F–I), but SHK did not affect mouse body weight (Fig. 1J), These results indicate that SHK not only suppresses tumor growth but also potentially mitigates cancer cachexia, or at minimum, demonstrates a favorable safety profile. Western blot and immunohistochemical (IHC) analyses of PDX tissues showed decreased expression of proliferation markers (PCNA and Ki-67), and the migration marker MMP-9 in the SHK-treated groups (Fig. 1 K–L), consistent with the results from the in vitro experiments. Collectively, these data indicate that SHK exhibits potent anti-LUAD effects in both cellular and animal models, with minimal toxicity.

SHK promotes apoptosis in LUAD cells in vitro and in vivo

We investigated our previously published thermal proteome profiling (TPP) [26] and solvent-induced protein precipitation (SIP) [27] datasets [21] and identified 22 candidate target proteins of SHK Fig. 2A–B). The GO enrichment analysis of biological processes revealed significant enrichment in “negative regulation of apoptotic process” (relative genes: PRDX5, ID1, FHL2, PDE3A, and SQSTM1) (P < 0.01) (Fig. 2C), indicating that SHK may exert its anti-LUAD effects primarily through the modulation of apoptotic pathways. These findings were further supported by experimental evidence: (1) Flow cytometry demonstrated that SHK treatment (48 h) induced apoptosis in A549 and H1299 cells in a concentration-dependent manner (Fig. 2D–E); (2) Western blot analysis showed that SHK upregulated increased the levels of pro-apoptotic proteins (cleaved-PARP, cleaved caspase-3, and BAX) while decreasing the levels of anti-apoptotic proteins (pro-PARP, pro-caspase-3, and Bcl-2) in A549 and H1299 cells and PDX tumors (Fig. 2F–H); (3) Quantitative analysis of TUNEL staining revealed a significant increase in apoptotic cell death in the SHK-treated group(Fig. 2I) ; (4) The quantitative analysis of IHC staining of PDX tumor sections confirmed increased BAX expression and decreased Bcl-2 expression in the high-dose SHK-treated group compared with those in the vehicle control group (Fig. 2J). These consistent findings across cellular and animal models show that SHK induces LUAD cell apoptosis through coordinated regulation of apoptotic networks.

Fig. 2.

Fig. 2

Fig. 2

SHK Promotes Apoptosis in LUAD. (A) Potential targets of SHK were identified through TPP and SIP experiments. (B) A total of 22 candidate targets were obtained through screening the P-values of each protein identified in the TPP and SIP assays. (C) Functional enrichment analysis of 22 potential SHK targets was conducted through the Divid platform, with visualization of analytical results being achieved using the bioinformatics online toolkit .D-E) The impact of SHK on LUAD cell apoptosis was evaluated through flow cytometric analysis .Western blot analysis confirmed upregulated expression of pro-apoptotic proteins (cleaved-PARP, cleaved caspase-3, BAX) along with downregulation of anti-apoptotic proteins (Pro-PARP, Pro-caspase-3, Bcl-2) in both A549 cell lines F), and H1299 cell lines G), and PDX model H) Each experiment was performed in triplicate. Data are shown as mean ± SD(* P < 0.05, ** P < 0.01, *** P < 0.001 vs.control). I) Apoptotic cells were detected by TUNEL staining, J) Immunohistochemical analysis of BAX and Bcl-2 expression patterns was performed in murine tumor tissues

FHL2 is the principal target mediating the proapoptotic effects of SHK on LUAD

We further investigate the molecular mechanism of SHK-triggered apoptosis, by analyzing the relationships between potential target proteins (PRDX5, FHL2, ID1, PDE3A, and SQSTM1) and patient s’ prognosis using TCGA database (https://portal.gdc.cancer.gov/). Expression profiling was performed using RNA-Seq data from 515 LUAD samples and 59 adjacent normal lung tissue samples, and the results showed that FHL2 and SQSTM1 levels were significantly increased in LUAD tissues compared with those in adjacent normal tissues. In contrast, PRDX5 and ID1 expression was markedly downregulated, while PDE3A levels remained unaltered (Fig. 3 A). Prognostic analysis via GEPIA2 (http://gepia2.cancer-pku.cn/), which integrates 483 LUAD samples from TCGA, revealed that only ID1 and FHL2 were significantly associated with patient outcomes (Fig. 3B). Because SHK mediates apoptosis by regulating the expression of genes that negatively regulate apoptosis (Fig. 2A)and ID1 has a paradoxical role in NSCLC and inconclusive function in regulating therapeutic responses to anticancer agents [28–30], elevated FHL2 expression predicts adverse clinical outcomes [31]. These findings indicate that FHL2 may serve as a novel therapeutic target through which SHK can trigger caspase-dependent apoptosis in LUAD. Validation using clinical samples further revealed that both the FHL2 mRNA and protein levels were significantly increasedin LUAD tissues compared with adjacent normal tissues (Fig. 3C-D). To further validate that FHL2 is a direct target of SHK, we performed rescue experiments. First, we successfully knocked down and overexpressed the FHL2 gene (Supplementary Figure S1 A–G). The results demonstrated that both FHL2 knockdown and SHK treatment significantly induced apoptosis, whereas their combination did not have a synergistic effect (Fig. 3E–F). Furthermore, apoptosis was markedly suppressed in FHL2-overexpressing cells, and SHK treatment effectively reversed the antiapoptotic effect induced by FHL2 overexpression (Fig. 3G–H). Collectively, these findings indicate that SHK induces tumor cell apoptosis through an FHL2-dependent mechanism.

Fig. 3.

Fig. 3

FHL2 as a potential target of SHK. A)The expression levels of the PRDX5, ID1, FHL2, PDE3A, and SQSTM1 genes in LUAD were analyzed through the analysis of data from TCGA. B)The association between the aforementioned target protein genes and patient survival was analyzed using the GEPIA2 database. C)The expression levels of the FHL2 gene in cancerous and adjacent non-cancerous tissues from clinical patients were quantitatively analyzed by qPCR. D)Western blotting analyzed the expression of the FHL2 protein in cancerous tissues. E-H) Apoptotic progression following FHL2 knockdown and overexpression was quantitatively analyzed using flow cytometry

SHK targets the FHL2 protein and promotes FHL2 degradation

We next examined the effect of SHK on FHL2 expression to further elucidate the molecular mechanism by which SHK induces apoptosis in LUAD cells via FHL2. Treatment of A549 and H1299 cells with increasing concentrations of SHK resulted in a dose-dependent reduction in FHL2 protein levels (Fig. 4A–B). A further reduction in intracellular FHL2 protein expression by SHK was confirmed by IF staining (Fig. 4C–D)), while FHL2 mRNA expression remained unaffected (Fig. 4E–F). These in vitro findings were corroborated in the LUAD PDX model, in which SHK treatment significantly decreased FHL2 protein expression and IHC staining intensity without altering FHL2 mRNA levels (Fig. 4H–I). These results indicated that SHK might promote FHL2 protein degradation. H1299 cells were treated with 1 µM SHK for 24 h, followed by the addition of cycloheximide (CHX, 50 µg/mL) to examine the effect of SHK on FHL2 protein stability. Cells were harvested at the indicated time points (0, 3, 6, and 9 h), and FHL2 protein levels were analyzed by Western blotting, which revealed a decrease in protein instability (Fig. 4J). The TPP and SIP results suggested a physical interaction between SHK and FHL2 (shown in Fig. 2A). CETSA further confirmed that SHK treatment markedly altered the thermal stability of the FHL2 protein in A549 cell lysates (Fig. 4K), suggesting a potential interaction between SHK and FHL2. Based on these experimental findings, we performed computational modeling to predict the structural basis of their molecularinteractions. Molecular docking predicted that SHK was bound to the FHL2 protein with a binding energy of – 7.16 kcal/mol, with hydrogen bond interactions occurring with Glu41, Trp61, Lys83, and Gln86 (Fig. 4L). Collectively, these results demonstrate that SHK promotes LUAD cell apoptosis by modulating FHL2 protein stability rather than its transcription.

Fig. 4.

Fig. 4

SHK modulates the expression and subcellular distribution of FHL2 protein. A-B) Western blotting was performed to assess FHL2 protein expression levels and quantify their changes in A549 and H1299 cell lines following treatment with varying concentrations of SHK. C-D) Immunofluorescence analysis was conducted to evaluate the expression and subcellular localization of FHL2 in A549 and H1299 cell lines after 48-hour SHK treatment. E-F) qPCR was performed to analyze FHL2 mRNA expression levels in A549 and H1299 cell lines. G) Western blotting analyzed FHL2 protein expression in tumor tissues of PDX model mice treated with varying doses of SHK. H) qPCR was performed to analyze FHL2 mRNA expression in tumor tissues. I) Immunohistochemistry was performed to assess FHL2 protein expression in tumor. J) Acceleration of FHL2 protein degradation by SHK was confirmed using CHX-mediated protein synthesis inhibition. K) CETSA results and analysis were performed by heating 549 cell lysate at various temperatures (39–60 °C) for 3 min, followed by analysis via Western blotting. The data are presented as the means±SD of at least three separate experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P <, 0.0001 via one-way analysis of variance (ANOVA). L) The binding sites and binding energies of SHK with FHL2 was predicted through molecular docking, with the amino acid sequences displayed in green, the small molecule compound (SHK) in red, and the hydrogen bonds formed in yellow

SHK reduces the interaction between FOXO1 and FHL2

Due to its unique structural characteristics, the FHL2 protein participates in cellular processes by interacting with various proteins (including transcription factors), and exerts specific environment-dependent effects on different cancers. Weexplored whether SHK influences FHL2 stability—potentially by disrupting its interactions with other proteins—by first using the STRING database (https://string-db.org) and the GeneMANIA platform (https://genemania.org) to predict FHL2-interacting proteins. Notably, the intersections of the results of both analyses revealed that FOXO1 and SIRT1 were key candidates (Fig. 5A–C). However, the prediction from the databases revealed a direct interaction between FHL2 and FOXO1, whereas the interaction between FHL2 and SIRT1 was indirect through FOXO1 (Fig. 5D). The basal expression levels of FHL2 and FOXO1 in A549 and H1299 cells were confirmed by Western blot analysis (Supplementary Fig. S5).Therefore, we hypothesize that SHK may disrupt the FHL2–FOXO1 interaction, thereby destabilizing the FHL2 protein and subsequently inducing apoptosis. We tested this hypothesis, by establishing Flag-FHL2-overexpressing A549 and H1299 cell lines. Coimmunoprecipitation (Co-IP) confirmed the robust interaction between FHL2 and FOXO1, which was significantly attenuated by SHK treatment (Fig. 5E–F). Furthermore, Flag-FHL2 and HA-FOXO1 were separately overexpressed in HEK293T cells, and co-IP experiments again demonstrated the FHL2–FOXO1 interaction and its inhibition by SHK treatment (Fig. 5G). Collectively, these results indicate that SHK interferes with the formation of the FHL2–FOXO1 complex, ultimately promoting apoptotic cell death.

Fig. 5.

Fig. 5

SHK reduces enhances the interaction between FOXO1 and FHL2 A). Protein-protein interaction (PPI) partners of FHL2 were identified using the STRING databases. B). Proteins Interacting with FHL2 are Predicted Using the GeneMANIA Database. C The Venn diagram was generated based on the overlapping interaction partners identified from the STRING and GeneMANIA databases.).D) Proteins interacting with FHL2 were predicted, and their intersection revealed an association between FOXO1 and SIRT1. E-F) The interaction between FHL2 and FOXO1 was confirmed by Co-IP, and SHK was shown to affect their binding in. F) HEK293T cells were co-transfected with eukaryotic plasmids expressing full-length FHL2-Flag and FOXO1-HA and subsequently treated with SHK. Whole-cell extracts were harvested and analyzed by co-immunoprecipitation (Co-IP) and western blotting with anti-Flag and anti-HA antibodies. H-I) Co-IP demonstrated specific binding of SHK to FHL2 protein, but not to FOXO1 protein

We expressed Flag-FHL2 and HA-FOXO1 separately in HEK293T cells to further elucidate the molecular mechanism by which SHK disrupts the FHL2–FOXO1 complex. After a preincubation with SHK andFlag-FHL2, we added HA-FOXO1 and continued the incubation. The immunoprecipitation results showed that SHK significantly reduced the interaction between FHL2 and FOXO1. Conversely, after SHK was preincubated with HA-FOXO1 and then with Flag-FHL2, the inhibitory effect of SHK on the interaction between FHL2 and FOXO1 disappeared (Fig. 5H–I). These results collectively demonstrate that SHK specifically targets the FHL2 protein, thereby effectively disrupting the formation of the FHL2–FOXO1 complex.

SHK up-regulates FOXO1 expression at the protein level

FOXO1, a critical member of the FOXO transcription factor family, plays a pivotal role in maintaining cellular homeostasis by regulating the balance between cell proliferation and apoptosis. The dysregulation of FOXO1 has been strongly implicated in tumorigenesis. We investigate the potential involvement of FOXO1 in the anticancer effects of SHK, by examining its expression following SHK treatment. As shown in Fig. 6A–B, SHK treatment did not significantly alter FOXO1 mRNA levels in A549 or H1299 cells. However, Western blot analysis revealed a dose-dependent increase in FOXO1 protein expression with increasing SHK concentrations (Fig. 6C–D). Consistent with these findings, qPCR analysis of PDX model mouse tissues revealed no notable change in FOXO1 mRNA expression (Fig. 6E). In contrast, both Western blotting and immunohistochemical (IHC) staining showed increased FOXO1 protein levels in SHK-treated tumor tissues compared with those in controls (Fig. 6F–G). These results suggest that SHK suppresses lung cancer growth by upregulating FOXO1 at the protein level, rather than through transcriptional regulation.

Fig. 6.

Fig. 6

SHK up-regulates FOXO1 expression at the protein level. A-B) FOXO1 mRNA expression was analyzed by qPCR. C-D) The effects of SHK on FOXO1 protein expression were evaluated by Western blot cell lines (A549 and H1299) following treatment with indicated concentrations of SHK. E) FOXO1 mRNA expression levels in PDX models were measured using qPCR. F-G) Animal models exhibited increased FOXO1 expression as demonstrated by Western blot and IHC. *P < 0.05, **P < 0.01, ***P < 0.001, ****P <, 0.0001 via one-way analysis of variance (ANOVA)

SHK promotes FOXO1 acetylation and nuclear translocation via disruption of the FHL2–FOXO1 complex

Previous studies have indicated that the formation of the FHL2/FOXO1 complex attenuates FOXO1 acetylation and reduces the intracellular level of FOXO1, ultimately suppressing apoptosis in cancer cells [32, 33]. In non-small cell lung cancer (NSCLC), reduced nuclear translocation of FOXO1 has been shown to alleviate tumor cell apoptosis [34]. Our present data demonstrate that SHK effectively disrupted the formation of the FHL2–FOXO1 complex. We investigate the functional outcomes of SHK-mediated complex disruption, we examined the molecular and phenotypic changes in FOXO1 following SHK treatment. We next assessed FOXO1 acetylation levels. As shown in Fig. 6H–I, SHK treatment significantly increased FOXO1 acetylation. Nuclear fractionation assays revealed markedly increased FOXO1 nuclear translocation following SHK treatment (Fig. 6J–K). These findings were further corroborated by immunofluorescence staining (Fig. 6L–M). Together, these results demonstrate that SHK disrupts the FHL2-FOXO1 complex, increases FOXO1 acetylation, promotes its nuclear translocation, and consequently induces apoptosis to inhibit lung cancer growth. We speculate that the mechanism by which SHK induces apoptosis in the treatment of LUAD is as follows (Fig. 7).

Fig. 7.

Fig. 7

SHK promotes FOXO1 acetylation and nuclear translocation via disruption of the FHL2–FOXO1 complex. A-B) Increased acetylation of FOXO1. C-D) Western blotting was performed to determine the expression and subcellular distribution of FOXO1 protein in nuclear and cytoplasmic fractions isolated from A549 and H1299 cell lines following 48-hour treatment with varying concentrations of SHK. E-F) Immunofluorescence analysis was performed to detect intracellular FOXO1 expression. The data are presented as the means±SD of at least three separate experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P <, 0.0001 via one-way analysis of variance (ANOVA). G) SHK impedes nuclear translocation of FHL2, disrupting its interaction with FOXO1. This enables FOXO1 to bind promoter regions of pro-apoptotic genes, enhancing their transcriptional activation and ultimately promoting apoptosis in lung adenocarcinoma cells

Discussion

Traditional Chinese medicine (TCM) has shown favorable efficacy in treating cardiovascular, cerebrovascular, digestive, and respiratory system diseases, as exemplified by the application of artemisinin for malaria treatment [35]; consequently, the active constituents derived from natural products are receiving increasing attention and thus a thorough exploration of their pharmacological mechanisms is imperative. SHK, a compound derived from Lithospermum erythrorhizon has been investigated primarily for its effects on inflammation and cancer [18], and its potent anticancer activity has been validated across a broad spectrum of malignancies, where it exerts antitumor effects through mechanisms such as the modulation of reactive oxygen species (ROS) levels [36], inhibition of the NF-κB signaling pathway [21], andactivation of p53-dependent apoptotic pathways [37]. In this study, SHK was shown to induces apoptosis in LUADcells both in vitro and in vivo by targeting FHL2, thereby influencing the formation of the FHL2-FOXO1 complex and increasing the level of FOXO1 acetylation.

In malignant tumors, the inhibition of apoptotic pathways confers a survival advantage to cancer cells, representing a key mechanism underlying tumor resistance and recurrence [38, 39]. Conventional cancer therapies, such as chemotherapy and radiotherapy, aim to induce cancer cell apoptosis. However, many cancer cells exhibit intrinsic or acquired resistance to these treatments or harbor defects in apoptotic pathways. Apoptosis, a programmed cell death process, occurs primarily through two pathways: the mitochondria-mediated intrinsic pathway and the death receptor-mediated extrinsic pathway. The intrinsic pathway is predominantly regulated by the Bcl-2 protein family, where the interaction between the antiapoptotic protein Bcl-2 and the proapoptotic protein Bax modulates mitochondrial outer membrane permeabilization (MOMP), leading to the release of cytochrome c (Cyto c) into the cytosol. Released Cyto c activates caspase-9, which subsequently cleaves and activates the downstream effector caspase-3 [40, 41]. The extrinsic pathway is initiated by the binding of death receptors to their ligands, ultimately resulting in caspase-3 activation and execution of apoptosis. Poly (ADP-ribose) polymerase (PARP) plays a unique biphasic role in regulating apoptosis. Under conditions of mild DNA damage, PARP promotes cell survival by initiating the base excision repair pathway [42]. Conversely, when DNA damage exceeds cellular repair capacity, hyperactivation of PARP triggers apoptosis [43]. In this study, flow cytometry initially confirmed that SHK significantly promoted tumor cell apoptosis. Further validation using Western blotting and IHC staining demonstrated that SHK upregulated the expression levels of key proapoptotic proteins. These findings collectively indicate that SHK exerts its antitumor activity by inducing tumor cell apoptosis. However, the lack of direct detection of caspase-9 and caspase-8 activation represents a limitation of this study. In future investigations, we will further validate the involvement of the intrinsic pathway by detecting caspase-9 activity or using selective inhibitors such as Z-LEHD-FMK.

Building on previous work in which TPP and SIP were used to identify SHK target proteins, bioinformatics analysis and molecular docking were employed to screen FHL2 as the target mediating SHK-induced apoptosis (Fig. 2A–C), We regret that we were unable to mutate the predicted docking residues to further validate the interaction in the current study. This limitation will be addressed in future investigations, in which site-directed mutagenesis studies are planned to confirm the binding interface between SHK and FHL2. FHL2 protein expression be significantly higher in LUAD tissues than in normal tissues, and its expression level was negatively correlated with survival time of patients [17, 31, 44], consistent with the results obtained from our clinical samples (Fig. 3C–D). Previous studies have utilized in vitro FHL2 knockdown to inhibit cancer cell migration, invasion, and angiogenesis; to induce apoptosis; a and to suppress metastatic dissemination in vivo [15]. However, the clinical application of this genetic approach remains largely unexplored. Pharmacologically targeting FHL2 protein expression, particularly in combination with TCM-based therapies such as SHK, represents a novel avenue for LUAD treatment and holds profound significance for the discovery of new molecularly targeted therapies. In this study, Western blot analysis revealed that FHL2 protein expression was significantly downregulated following SHK treatment both in vitro and in vivo, whereas no alteration was observed at the transcript level. The promotion of FHL2 protein degradation by SHK was further confirmed by CHX chase assays (Fig. 4J). FHL2 knockdown promoted knockdown promoted tumor cell apoptosis; however, no additive apoptotic effect was observed when FHL2-knockdown cells were treated with SHK (Fig. 3I–G). Collectively, these results establish FHL2 as the critical direct binding target through which SHK-mediated apoptosis and tumor growth suppression are occur. A limitation of this study is that the specific pathway responsible for FHL2 degradation was not further explored.

The LIM domain, a cysteine-rich zinc finger motif, facilitates protein‒protein interactions [45]. FHL2, through interactions with other cellular proteins, participates in the regulation of vital cellular functions, including gene expression, signal transduction, cell adhesion, proliferation, and survival [46]. Within the prostate, FHL2 suppresses FOXO1 activity in prostate cancer cells by facilitating the deacetylation of FOXO1 and enhancing of the interaction between SIRT1 and FOXO1, thereby inhibiting tumor cell apoptosis [32]. Furthermore, FOXO1 deacetylation is associated with increased ubiquitination and subsequently decreased expression in cells; conversely, the suppression of deacetylation promotes its nuclear accumulation [34, 47]. The knockdown of the FHL2 gene has been reported to increase FOXO1 expression in the nucleus [48].Therefore, reducing the formation of the FHL2-FOXO1 complex may represent a novel therapeutic strategy for improving survival outcomes in LUAD patients. In this study, co-IP assays confirmed that SHK disrupted the formation of the FHL2-FOXO1 complex formation in vitro (Fig. 5E–I). Nuclear accumulation of FOXO1 was observed, and subcellular fractionation assays confirmed that FOXO1 expression in the nucleus was increased by SHK treatment. FOXO1, a crucial member of the FOXO family, acts as a transcription factor. Its dysregulation disrupts the balance between cell proliferation and death and is closely associated with tumorigenesis. FOXO1 undergoes diverse posttranslational modifications, including phosphorylation, methylation, acetylation, and ubiquitination, and interacts with multiple signaling pathways, such as the PI3K/Akt, EZH2/STAT3, JAK/STAT3, MAPK/ERK, Wnt/β-catenin, and NF-κB/Snail pathways, thereby regulating tumor cell proliferation, apoptosis, and progression [49]. Recent reports highlight the role of FOXO1 in limiting CAR-T- cell exhaustion and increasing antitumor activity [50, 51]. Cinobufagin induces FOXO1-regulated apoptosis, by inhibiting G9a in non-small cell lung cancer A549 cells [52]. Hyperoside, a flavonol glycoside, inhibits NSCLC cell proliferation and induces apoptosis by regulating the EGFR/ERK/FOXO1 signaling pathway [53]. Deoxypodophyllotoxin (DPT), a natural lignan, suppresses LUAD progression by reducing FOXO1 phosphorylation and promoting its nuclear translocation [54]. The aqueous extract of Actinidia eriantha Benth. root inhibits NSCLC through modulation of the TGF-β/FOXO/mTOR pathway [55]. Unlike the aforementioned agents that primarily modulate FOXO1 phosphorylation or upstream signaling, our study reveals a novel mechanism whereby SHK directly targets FHL2, disrupts the FHL2-FOXO1 complex, and enhances FOXO1 acetylation and nuclear translocation, thereby providing a distinct molecular basis for FOXO1 activation by natural products. Multiple studies have shown decreased FOXO1 expression in various solid tumors, and FOXO1 can induce apoptosis in human LUAD cells by upregulating its target gene Bim via the PI3K/Akt pathway [56]. Notably, Jeung et al. [57]. revealed that SHK induces apoptosis in lung cancer cells through activation of the FOXO3a/EGR1/SIRT1 signaling axis, in which SIRT1 plays a central role in mediating SHK-induced apoptosis. Interestingly, our bioinformatics analysis also identified SIRT1 as an FHL2-interacting protein (Fig. 5A–D), suggesting potential crosstalk between the FHL2-FOXO1 axis and SIRT1-mediated pathways. While Jeung et al. focused on FOXO3a, our study identifies FOXO1 is a key downstream effector of SHK, indicating that SHK may exert its pro-apoptotic effects through multiple FOXO family members in a context-dependent manner. Consequently, increasing FOXO1 expression in tumor cells can inhibit proliferation. FHL2 is aberrantly overexpressed in LUAD and correlates with a poor prognosis, whereas low FOXO1 expression is associated with reduces the 5-year survival rates, suggesting that their reciprocal expression pattern may serve as a novel prognostic biomarker. This study confirmed the FHL2–FOXO1 interaction and demonstrated that SHK reduces the formation of this complex. Western blot and immunofluorescence assays further confirmed the increased nuclear accumulation of FOXO1. The elevated expression of the FOXO1 protein promoted tumor cell apoptosis, which was validated in this study. Despite the comprehensive mechanistic insights into SHK-induced apoptosis through the FHL2-FOXO1 axis in LUAD, several limitations should be acknowledged in the present study.First, although the patient-derived xenograft (PDX) model employed in this study effectively recapitulates the heterogeneity of patient tumors, we did not generate FHL2-knockout mice to validate the target specificity of SHK in an immunocompetent and physiologically relevant setting. Second, while our data demonstrate that SHK promotes FHL2 protein degradation, the precise degradation pathway—whether through the ubiquitin-proteasome system or the autophagy-lysosomal pathway—and the specific E3 ligase responsible for this process remain to be determined. Furthermore, the exact ubiquitination sites on FHL2 require identification through mass spectrometry-based analysis in future investigations.

Conclusion

In conclusion, our study demonstrated that SHK significantly inhibits LUAD growth both in vitro and in vivo. Mechanistically, SHK targets FHL2 to disrupt the formation of the FHL2–FOXO1 complex, promoting FHL2 degradation while increasing FOXO1 acetylation and nuclear translocation. These changes activate the downstream caspase signaling cascade, inducing apoptosis and ultimately suppressing tumor growth. Our findings elucidate the molecular mechanism of SHK-mediated LUAD inhibition through the FHL2-FOXO1 signaling axis, providing not only a novel theoretical foundation for its clinical application but also new perspectives for he development of therapeutic drugs targeting this pathway for LUAD treatment.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary Material 2 (212.1KB, pdf)

Acknowledgements

This study was supported by the Liaoning Provincial Science and Technology Program Joint Plan (Natural Science Foundation-General Program, Grant No. 2024-MSLH-087), the Dalian Science and Technology Innovation Fund Project (Grant No. 2022DF040), and the Postdoctoral Fellowship Program of CPSF (Grant No. GZB20250895).

Author contributions

Shiqun Chen: Writing - original draft, Investigation. Meirong Zhou: Data curation. Wen Zhang: Methodology, Formal analysis. Jiyong Zhong: Formal analysis. Wenqian Han: Software, Methodology. Zhaoxuan Wang: Methodology, Software. Shiqing Wang: Resources, Project administration. Chundong Gu: Data curation, Conceptualization. Zhenlong Yu: Writing e review & editing, Supervision. Shilei Zhao: Writing - review & editing, Supervision, Funding acquisition.

Data availability

All relevant data are presented in the manuscript and its Supplementary Information. The source data underlying the figures, including raw values for statistical analyses, are provided as a Source Data file. Uncropped scans of all blots and original microscopy images have been included as part of the Supplementary Information. Full datasets are permanently archived and available from the corresponding author upon request.

Declarations

Competing interest

The author declares no conflict of interest.

Footnotes

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Shiqun Chen, Meirong Zhou, Wen Zhang and Jiyong Zhong are Co-first authors.

Contributor Information

Zhenlong Yu, Email: qdyuzl871123@163.com.

Shilei Zhao, Email: bbstnt@126.com.

References

  • 1.Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023;20:624–39. [DOI] [PubMed] [Google Scholar]
  • 2.Hendriks LEL, Remon J, Faivre-Finn C, Garassino MC, Heymach JV, Kerr KM, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2024;10(1):71. [DOI] [PubMed] [Google Scholar]
  • 3.Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27:1345–56. [DOI] [PubMed] [Google Scholar]
  • 4.Suresh K, Naidoo J, Lin CT, Danoff S. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. Chest. 2018;154:1416–23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Tan AC, Tan DS. W. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J Clin Oncol. 2022;40:611–25. [DOI] [PubMed] [Google Scholar]
  • 6.Shu J, Jiang J, Zhao G. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis. Front Immunol. 2023;14:1177847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Verset L, Feys L, Trépant A-L, De Wever O, Demetter P. FHL2: a scaffold protein of carcinogenesis, tumour-stroma interactions and treatment response. Histol Histopathol. 2016;31:469–78. [DOI] [PubMed] [Google Scholar]
  • 8.Wixler V, Geerts D, Laplantine E, Westhoff D, Smyth N, Aumailley M, et al. The LIM-only protein DRAL/FHL2 binds to the cytoplasmic domain of several alpha and beta integrin chains and is recruited to adhesion complexes. J Biol Chem. 2000;275(43):33669–78. [DOI] [PubMed] [Google Scholar]
  • 9.Liu Z, Han S, Wang Y, Cui C, Zhu Q, Jiang X, et al. The LIM-Only Protein FHL2 is involved in Autophagy to Regulate the Development of Skeletal Muscle Cell. Int J Biol Sci. 2019;15(4):838–46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Lai CF, Bai S, Uthgenannt BA, Halstead LR, McLoughlin P, Schafer BW, et al. Four and half lim protein 2 (FHL2) stimulates osteoblast differentiation. J Bone Miner Res. 2006;21(1):17–28. [DOI] [PubMed] [Google Scholar]
  • 11.Jiang T, Zeng Q, Wang J. Unlocking the secrets of Cardiac development and function: the critical role of FHL2. Mol Cell Biochem. 2025;480:2143–57. [DOI] [PubMed] [Google Scholar]
  • 12.Liu X, Yang M, Li J, Liu H, Dong Y, Zheng J, et al. Identification of CFH and FHL2 as biomarkers for idiopathic pulmonary fibrosis. Front Med (Lausanne). 2024;11:1363643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Zhang J, Zeng Q, She M. The roles of FHL2 in cancer. Clin Exp Med. 2023;23:3113–24. [DOI] [PubMed] [Google Scholar]
  • 14.Bai S, Zha J, Zhao H, Ross FP, Teitelbaum SL. Tumor necrosis factor receptor-associated factor 6 is an intranuclear transcriptional coactivator in osteoclasts. J Biol Chem. 2008;283:30861–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Li N, Xu L, Zhang J, Liu Y. High level of FHL2 exacerbates the outcome of non-small cell lung cancer (NSCLC) patients and the malignant phenotype in NSCLC cells. Int J Exp Pathol. 2022;103:90–101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Chen T, Chen J, Chen Q, Liang Z, Pan L, Zhao J, et al. Promotion of non-small cell lung cancer tumor growth by FHL2 via inducing angiogenesis and vascular permeability. J Thorac Dis. 2024;16(2):1424–37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Kanzaki R, Reid S, Bolivar P, Sjölund J, Staaf J, Larsson S, et al. FHL2 expression by cancer-associated fibroblasts promotes metastasis and angiogenesis in lung adenocarcinoma. Int J Cancer. 2025;156(2):431–46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Mollaei S, Khanehbarndaz O, Gerami-Khashal Z, Ebadi M. Molecular identification and phytochemical screening of endophytic fungi isolated from Lithospermum officinale L. roots: A new source of shikonin. Phytochemistry. 2019;168:112116. [DOI] [PubMed] [Google Scholar]
  • 19.Iranzadeh S, Dalil D, Kohansal S, Isakhani M. Shikonin in breast cancer treatment: a comprehensive review of molecular pathways and innovative strategies. J Pharm Pharmacol. 2024;76:967–82. [DOI] [PubMed] [Google Scholar]
  • 20.Wang YY, Midie X, Cheng L, Xin W, Xiaoyan Z, Weiqi S, et al. Induction of ferroptosis by shikonin in gastric cancer via the DLEU1/mTOR/GPX4 axis. Cell Biol Int. 2025;49:757–71. [DOI] [PubMed] [Google Scholar]
  • 21.Yu Z, Gao J, Zhang X, Peng Y, Wei W, Xu J et al. Characterization of a small-molecule inhibitor targeting NEMO/IKKβ to suppress colorectal cancer growth. Signal Transduct Target Ther. 2022;7(1):71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Sun Q, Gong T, Liu M, Ren S, Yang H, Zeng S, et al. A naphthalene ingredient: Therapeutic actions, pharmacokinetics, toxicology, clinical trials and pharmaceutical researches. Phytomedicine. 2022;94:153805. [DOI] [PubMed] [Google Scholar]
  • 23.Liang J, Tian X, Zhou M, Yan F, Fan J, Qin Y, et al. Shikonin and chitosan-silver nanoparticles synergize against triple-negative breast cancer through RIPK3-triggered necroptotic immunogenic cell death. Biomaterials. 2024;309:122608. [DOI] [PubMed] [Google Scholar]
  • 24.Bin L, Zongqi W, Ye D, Xuanzhong W, Shan L, Chongcheng W, et al. RIP1 and RIP3 contribute to shikonin-induced glycolysis suppression in glioma cells via increase of intracellular hydrogen peroxide. Cancer Lett. 2018;425:31–42. [DOI] [PubMed] [Google Scholar]
  • 25.Tang L, Yin Y, Cao Y, Fu C, Liu H, Feng J, et al. Extracellular vesicles-derived hybrid nanoplatforms for amplified CD47 blockade-based cancer immunotherapy. Adv Mater. 2023;35(35): e2303835. [DOI] [PubMed] [Google Scholar]
  • 26.Franken H, Mathieson T, Childs D, Sweetman GM, Werner T, Tögel I, et al. Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry. Nat Protoc. 2015;10(10):1567–93. [DOI] [PubMed]
  • 27.Xiaolei Z, Qi W, Yanan L, Chengfei R, Shuyue W, Lianghai H, et al. Solvent-induced protein precipitation for drug target discovery on the proteomic scale. Anal. Chem. 7;92(1):1363–71. [DOI] [PubMed]
  • 28.Cheng YJ, Lee YC, Chiu WC, Tsai JW, Su YH, Hung AC, et al. High Id1 expression, a generally negative prognostic factor, paradoxically predicts a favorable prognosis for adjuvant paclitaxel plus cisplatin therapy in surgically treated lung cancer patients. Oncotarget. 2014;5(22):11564–75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Ponz-Sarvisé M, Nguewa PA, Pajares MJ, et al. Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance. Clin Cancer Res 2011;17(12):4155–66. [DOI] [PubMed] [Google Scholar]
  • 30.Tan HY, Wang N, Chan YT, Zhang C, Guo W, Chen F, et al. ID1 overexpression increases gefitinib sensitivity in non-small cell lung cancer by activating RIP3/MLKL-dependent necroptosis. Cancer Lett. 2020;475:109–18. [DOI] [PubMed] [Google Scholar]
  • 31.Xu J, Zhang Y, Li M, Shao Z, Dong Y, Li Q, et al. A single-cell characterised signature integrating heterogeneity and microenvironment of lung adenocarcinoma for prognostic stratification. EBio Med. 2024;102:105092. [DOI] [PMC free article] [PubMed]
  • 32.Yang Y, Hou H, Haller EM, Nicosia SV, Bai W. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J. 2005;24(5):1021–32. [DOI] [PMC free article] [PubMed]
  • 33.Kitamura YI, Kitamura T, Kruse JP, Raum JC, Stein R, Gu W, et al. FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metab. 2005;2(3):153–63. [DOI] [PubMed] [Google Scholar]
  • 34.Zhang Y, Sun C, Xiao G, et al. S-nitrosylation of the peroxiredoxin-2 promotes S-nitrosoglutathione-mediated lung cancer cells apoptosis via AMPK-SIRT1 pathway. Cell Death Dis 2019;10:329. [DOI] [PMC free article] [PubMed]
  • 35.Daily JP, Minuti A, Khan N. Diagnosis, treatment, and prevention of Malaria in the US: a review. JAMA. 2022;328(5):460–71. [DOI] [PubMed]
  • 36.Lu C, Zhang Z, Fan Y, Wang X, Qian J, Bian Z. Shikonin induces ferroptosis in osteosarcomas through the mitochondrial ROS-regulated HIF-1α/HO-1 axis. Phytomedicine. 2024;135:156139. [DOI] [PubMed]
  • 37.Pan J, Li M, Yu F, Zhu F, Wang L, Ning D, et al. Up-Regulation of p53/miR-628-3p Pathway, a Novel Mechanism of Shikonin on Inhibiting Proliferation and Inducing Apoptosis of A549 and PC-9 Non-Small Cell Lung Cancer Cell Lines. Front Pharmacol. 2021;12:766165. [DOI] [PMC free article] [PubMed]
  • 38.Gao W, Wang X, Zhou Y, et al. Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. Sig Transduct Target Ther 2022;7:196. [DOI] [PMC free article] [PubMed]
  • 39.He X, Ma Y, Wen Y, Zhang R, Zhao D, Wang G, et al. Tumor-derived apoptotic extracellular vesicle-mediated intercellular communication promotes metastasis and stemness of lung adenocarcinoma. Bioact Mater. 2024;36:238–55. [DOI] [PMC free article] [PubMed]
  • 40.Rosa N, Speelman-Rooms F, Parys JB, Bultynck G. Modulation of Ca2+ signaling by antiapoptotic Bcl-2 versus Bcl-xL: From molecular mechanisms to relevance for cancer cell survival. Biochim Biophys Acta Rev Cancer. 2022;1877(6):188791. [DOI] [PubMed]
  • 41.Eskandari E, Eaves CJ. Paradoxical roles of caspase-3 in regulating cell survival, proliferation, and tumorigenesis. J Cell Biol. 2022;221(6):e202201159. [DOI] [PMC free article] [PubMed]
  • 42.Zielińska Z, Ołdak Ł, Gorodkiewicz E. Methods of PARP-1 Determination and its importance in living organisms. Protein Pept Lett. 2022;29(6):496–504. [DOI] [PubMed]
  • 43.V S-B, T, A., A S-K. Apoptotic proteins with non-apoptotic activity: expression and function in cancer. Apoptosis: an international journal on programmed cell death. 2023;28. [DOI] [PMC free article] [PubMed]
  • 44.Wang S, Liu B, Su Y, Wang N, Dong P, Xu X, et al. FHL2 promotes the aggressiveness of lung adenocarcinoma by inhibiting autophagy via activation of the PI3K/AKT/mTOR pathway. Thorac Cancer. 2024;15(8):630–41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Johannessen M, Møller S, Hansen T, Moens U, Van Ghelue M. The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell Mol Life Sci. 2006;63(3):268–84. [DOI] [PMC free article] [PubMed]
  • 46.Cao CY, Mok SW, Cheng VW, Tsui SK. The FHL2 regulation in the transcriptional circuitry of human cancers. Gene. 2015;572(1):1–7. [DOI] [PMC free article] [PubMed]
  • 47.Yang Y, Zhao Y, Liao W, Yang J, Wu L, Zheng Z, et al. Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment. Neoplasia. 2009;11(4):313–24. [DOI] [PMC free article] [PubMed]
  • 48.Habibe JJ, Clemente-Olivo MP, Scheithauer TPM, et al. Glucose-mediated insulin secretion is improved in FHL2-deficient mice and elevated FHL2 expression in humans is associated with type 2 diabetes. Diabetologia. 2022;65(10):1721–33. [DOI] [PMC free article] [PubMed]
  • 49.Ebrahimnezhad M, Natami M, Bakhtiari GH, Tabnak P, Ebrahimnezhad N, Yousefi B, et al. FOXO1, a tiny protein with intricate interactions: Promising therapeutic candidate in lung cancer. Biomed Pharmacother. 2023;169:115900. [DOI] [PubMed]
  • 50.Chan JD, Scheffler CM, Munoz I, et al. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature. 2024;629:201–10. [DOI] [PMC free article] [PubMed]
  • 51.Doan AE, Mueller KP, Chen AY, et al. FOXO1 is a master regulator of memory programming in CAR T cells. Nature. 2024:629:211–18. [DOI] [PMC free article] [PubMed]
  • 52.Cui Y, Wu X, Jin J, Man W, Li J, Li X, et al. CircHERC1 promotes non-small cell lung cancer cell progression by sequestering FOXO1 in the cytoplasm and regulating the miR-142-3p-HMGB1 axis. Mol Cancer. 2023;22(1):179. [DOI] [PMC free article] [PubMed]
  • 53.Xu S, Zou Y, Luo G, Tang L, Zhan H, Huang L, et al. Mechanistic evaluation of hyperoside against non-small cell lung cancer: a combined approach of network pharmacology and in vitro experimental validation. Discov Oncol. 2025;16(1):1757. [DOI] [PMC free article] [PubMed]
  • 54.Hu Z, Zhao P, Xu H, et al. Hyperoside exhibits anticancer activity in non‑small cell lung cancer cells with T790M mutations by upregulating FoxO1 via CCAT1. Oncol Rep. 2020;43:617–24. [DOI] [PubMed]
  • 55.Zhang X, Xiao Q, Chen H, Yang S, Li Q, Peng L. Actinidia eriantha Benth. Root as a New Phytomedicine Inhibits Non-Small Cell Lung Cancer by Regulating TGF-β/FOXO/mTOR. Int J Mol Sci. 2025;26(18):8957. [DOI] [PMC free article] [PubMed]
  • 56.Deng R, Tang J, Xie B, Feng G, Huang Y, Liu ZC, et al. SYUNZ‐16, a newly synthesized alkannin derivative, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of AKT/FOXO signal pathway. Int J Cancer 2010;127. [DOI] [PubMed]
  • 57.Jeung YJ, Kim HG, Ahn J, et al. Shikonin induces apoptosis of lung cancer cells via activation of FOXO3a/EGR1/SIRT1 signaling antagonized by p300. Biochimica et Biophysica Acta. 2016;1863(11):2584–93. [DOI] [PubMed]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Material 2 (212.1KB, pdf)

Data Availability Statement

All relevant data are presented in the manuscript and its Supplementary Information. The source data underlying the figures, including raw values for statistical analyses, are provided as a Source Data file. Uncropped scans of all blots and original microscopy images have been included as part of the Supplementary Information. Full datasets are permanently archived and available from the corresponding author upon request.


Articles from Journal of Translational Medicine are provided here courtesy of BMC

RESOURCES